重组人血小板生成素、重组人白介素-11预防卵巢癌化疗患者血小板减少症的对比研究

Comparative Study of Recombinant Human Thrombopoietin and Recombinant Human Interleukin-11 in Preventing Thrombocytopenia in Patients with Ovarian Cancer Undergoing Chemotherapy

目的 对比重组人血小板生成素(rhTPO)、重组人白介素-11(rhIL-11)预防卵巢癌化疗患者血小板减少症(CIT)的效果。方法 选取2020年3月至2022年3月商丘市第四人民医院收治的80例卵巢癌化疗患者,按随机数字表法分为两组,各40例。rhTPO组预防性使用rhTPO,rhIL-11组预防性使用rhIL-11。比较两组预防性用药后1个周期内CIT的发生率;比较两组用药前、用药结束时的血小板最低值及凝血指标;比较两组预防性用药后血小板恢复正常时间及不良反应发生率。结果 rhTPO组的CIT发生率低于rhIL-11组,差异有统计学意义(P<0.05);用药结束时,两组血小板最低值较用药前升高,且rhTPO组高于rhIL-11组(P<0.05)。预防性用药后,rhTPO组血小板恢复至(75~100)×10^(9)/L、≥100×10^(9)/L的时间均短于rhIL-11组(P<0.05)。用药前、用药结束时,两组患者纤维蛋白原、凝血酶原时间、凝血酶时间、部分活化凝血活酶时间比较,差异无统计学意义(P>0.05);两组患者用药结束时的纤维蛋白原、凝血酶原时间、凝血酶时间、部分活化凝血活酶时间与用药前比较,差异无统计学意义(P>0.05)。rhTPO组的不良反应总发生率较rhIL-11组低(P<0.05)。结论 rhTPO、rhIL-11均可预防卵巢癌化疗患者CIT的发生,相较rhIL-11,rhTPO预防CIT的效果更显著,能有效改善血小板最低值,加快血小板恢复正常,降低不良反应的发生率,且不影响患者的凝血功能。

Objective To compare the effects of recombinant human thrombopoietin(rhTPO)and recombinant human interleukin-11(rhIL-11)in preventing thrombocytopenia(CIT)in patients with ovarian cancer undergoing chemotherapy.Methods 80 patients with ovarian cancer treated in Shangqiu No.4 People's Hospital from March 2020 to March 2022 were randomly divided into two groups,40 patients in each group.rhTPO group was treated with rhTPO prophylactically,and rhIL-11 group was treated with rhIL-11 prophylactically.The incidence of CIT in one cycle after preventive medication was compared between the two groups.The minimum platelet value and coagulation index before and after treatment were compared between the two groups.The platelet recovery time and the incidence of adverse reactions were compared between the two groups.Results The incidence of CIT in rhTPO group was lower than that in rhIL-11 group,and the difference was statistically significant(P<0.05).At the end of the treatment,the minimum platelet value of the two groups was higher than that before,and the rhTPO group was higher than the rhIL-11 group(P<0.05).After prophylactic administration,the time of platelet recovery to(75-100)×10^(9)/L and≥100×10^(9)/L in rhTPO group was shorter than that in rhIL-11 group(P<0.05).There was no significant difference in fibrinogen,prothrombin time,thrombin time and partially activated thromboplastin time between the two groups at the end of treatment and before treatment(P>0.05).The total incidence of adverse reactions in rhTPO group was lower than that in rhIL-11 group(P<0.05).Conclusion rhTPO and rhIL-11 can prevent the occurrence of CIT in ovarian cancer patients undergoing chemotherapy.Compared with rhIL-11,rhTPO has a more significant effect in preventing CIT,which can effectively improve the minimum value of platelets,accelerate the recovery of platelets to normal,reduce the incidence of adverse reactions,and not affect the coagulation function of patients.